Navigation Links
ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Date:7/29/2010

x patients who stopped all treatment at Week 24 were part of an investigation of response-guided treatment duration for ANA598 in which patients who had achieved undetectable levels of virus (<15 IU/mL) at Weeks 4 and 12 were randomized 1:1 to stop all treatment at Week 24 or Week 48.  In addition to the six patients who stopped treatment at Week 24, six patients in the 200 mg bid arm are continuing to receive SOC alone through Week 48 for comparison purposes.  Additionally, 14 patients from the ANA598 400 mg bid arm and 4 patients from the control arm (receiving placebo plus SOC) met the stopping criteria and have been randomized to stop all treatment at Week 24 or 48.  The initial post-treatment results from these latter arms are expected later this year for those patients who stopped therapy at Week 24.

Conference Call Webcast and Slides

Anadys will hold a conference call and webcast today, Thursday, July 29, 2010 at 8:30 a.m. Eastern Daylight Time to discuss the post-treatment results from the ongoing Phase II combination study and Anadys' second quarter 2010 financial results   A live webcast of the call, including accompanying slides, will be available online at www.anadyspharma.com.  A telephone replay with slides will also be available approximately one hour after completion of the call.  To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 28631163.  The webcast and telephone replay will be available through August 12, 2010.

Phase II Combination Study


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
11. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014  As the Medical Affairs, role has ... in this area are exploring methods to develop strong ... Affairs Consortium at Best Practices, LLC is designed to ... about the key challenges they face. The consortium will ... three virtual roundtable discussions where leaders discuss key findings ...
(Date:8/22/2014)... 22, 2014 MC Medical, a subsidiary of Mitsubishi ... Columbus, OH medical device company, have formally ... and robotic visualization system in Japan . ... in Japan in the latter half ... an extensive product portfolio in endoscopic surgery market in ...
(Date:8/22/2014)... , Cali ., Aug. 22, 2014 ... Papillomavirus Conference shows that a therapy being developed by Hera ... two that cause 70 percent of all cervical cancer. ... blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according ... Broker , Ph.D., who presented the findings at the ...
Breaking Medicine Technology:Best Practices' Medical Affairs Consortium Survey Has Achieved Strong Participation 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... Aug. 9, 2011 PAREXEL International Corporation (NASDAQ: ... fourth quarter and fiscal year ended June 30, 2011. ... 30, 2011 consolidated service revenue increased by 5.2% to ... year period.  Excluding the positive impact from foreign exchange ...
... The HITECH Act is a law that requires healthcare ... this online data is at the forefront of many leading ... a thought-leader in HIPAA and HITECH compliance, has been asked ... tradeshow during a speaking session on Wednesday, August 10. ...
Cached Medicine Technology:PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 2PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 3PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 4PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 5PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 6PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 7PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 8PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 9PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 10PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 11PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 12PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 13HITECH Act Puts Security of Electronic Medical Records in Hands of Hosting Providers 2
(Date:8/22/2014)... complex autoimmune disease that affects 1 to 2 ... cope with pain, disability and joint disfigurements, but ... life and marital functioning. While many pharmacological advances ... is common. In addition, some patients avoid newer ... effects. Because of this, there is interest in ...
(Date:8/22/2014)... Eagerly embracing intended parents around the globe, ... offers the top male infertility programs — run by ... network of IVFinMexico.com continues to shape modern ... female and male infertility, advanced research and education. , ... eminently set by company CEO and Founder Tolga Umar ...
(Date:8/22/2014)... time provides an opportunity for parents to develop an ... expert suggests. "Forget New Year,s resolutions; the start ... start of a new fitness and exercise program for ... University of the Sciences in Philadelphia, said in a ... to build up, "it,s important for mom and dad ...
(Date:8/22/2014)... again attained the distinguished Magnet hospital designation by ... Program. Considered the gold standard for nursing excellence, ... and professionalism. It is the top international credential ... redesignate Newport Hospital was based on the hospital,s ... practice. , "It is a privilege for us ...
(Date:8/22/2014)... News) -- Many children get anxious or afraid when ... a number of ways that parents can make these ... The first step is to explain to children in ... health, said Rita John, director of the pediatric primary ... Nursing in New York City. "Children need to ...
Breaking Medicine News(10 mins):Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 2Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 4Health News:With Kids in School, Parents Can Work Out 2Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2Health News:Simple Steps Make Shots Less Scary for Kids, Nurse Says 2
... Rochelle, NY, November 1, 2011Clinicians often face the challenge ... parents, teachers, and children about a child,s behavioral problems. ... of these disagreements may provide important information that could ... the current issue of Journal of Child and ...
... take aspirin for a headache, thank a willow tree. ... found in willow tree bark and is made by ... mimicking the chemical production processes of plants, scientists have ... alkaloid drug products, including caffeine, atropine (an anti-spasmodic used ...
... million expanded initiative sponsored by the National Institutes of ... cardiovascular disease and to assess potential new treatments in ... Americans have diabetes, the seventh leading cause of death ... of heart disease, stroke, kidney disease, blindness and amputation. ...
... undergoing percutaneous coronary intervention (PCI), also known as ... than men. Risk-adjusted analyses have now indicated that, ... independent mortality predictor following PCI according to the ... Interventions , a journal published by Wiley-Blackwell on ...
... recent study published in the November issue of the ... many radiologists disagree on the management of incidental findings ... finding is something found that is unrelated to the ... in CT resolution have improved radiologists, ability to identify ...
... of a study being published online Oct. 31, 2011, in the ... women who carry mutations in a BRCA gene - but who ... an increased risk of developing breast cancer compared to relatives of ... results run counter to a previous study showing a higher risk ...
Cached Medicine News:Health News:Conflicting views of a child's behavior problems from parents, teachers, and the child may be helpful to clinician 2Health News:Plant researchers locate transporter used for nicotine metabolism 2Health News:ASU leads $5 million NIH-sponsored research initiative to advance diabetes care and treatment 2Health News:ASU leads $5 million NIH-sponsored research initiative to advance diabetes care and treatment 3Health News:Women undergoing PCI display greater number of co-morbidities than men 2Health News:Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation 2Health News:Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: